Grail (GRAL) stock shot up 33% Thursday, the day after the company announced a partnership with Quest (DGX) to expand ...

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

Shares of Grail, a medical technology company, jumped 20% Wednesday to lead Nasdaq 100 gainers. Grail spun off from Illumina last year, and is developing a number of early detection cancer screening ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

CHICAGO: US cancer diagnostic test maker Grail, which was due to list its shares on the Nasdaq yesterday after being spun out of Illumina, is betting that commercial partnerships with health ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of ...

The ECJ’s Illumina/Grail judgment has curtailed the Commission’s direct oversight of certain transactions, thereby elevating the need for national "call-in" powers. These call-in regimes ...

Please be advised that today's conference is being recorded. I would now like to hand the conference over to Sally Schwartz, Vice President of Investor Relations. Hello everyone and welcome to our ...

Grail spun off from Illumina last year, and is developing a number of early detection cancer screening products. Last week, Grail said it sees fiscal 2025 sales of its Galleri blood test up 20% to ...